Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allient Inc. stock logo
ALNT
Allient
$33.83
-1.3%
$26.82
$16.91
$35.13
$572.71M1.47116,444 shs130,413 shs
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$9.03
+1.9%
$6.54
$3.91
$13.99
$621.36M1.61819,335 shs822,461 shs
Transcat, Inc. stock logo
TRNS
Transcat
$79.16
+2.3%
$82.37
$67.56
$147.12
$737.61M0.7586,975 shs184,140 shs
10x Genomics, Inc. stock logo
TXG
10x Genomics
$10.41
-1.6%
$8.75
$6.78
$24.76
$1.28B1.992.55 million shs2.24 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allient Inc. stock logo
ALNT
Allient
-1.31%+6.05%+7.29%+43.04%+29.17%
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
+1.92%+1.01%+64.48%+38.50%-3.11%
Transcat, Inc. stock logo
TRNS
Transcat
+2.29%+1.51%-0.16%+9.08%-36.65%
10x Genomics, Inc. stock logo
TXG
10x Genomics
-1.61%+10.51%+14.14%+0.68%-51.24%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allient Inc. stock logo
ALNT
Allient
2.7267 of 5 stars
1.33.01.70.03.32.52.5
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
2.2146 of 5 stars
3.52.00.00.03.31.70.0
Transcat, Inc. stock logo
TRNS
Transcat
2.9256 of 5 stars
3.33.00.00.01.71.71.9
10x Genomics, Inc. stock logo
TXG
10x Genomics
4.2032 of 5 stars
4.21.00.04.81.32.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allient Inc. stock logo
ALNT
Allient
2.50
Moderate Buy$31.00-8.37% Downside
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
3.00
Buy$25.38181.01% Upside
Transcat, Inc. stock logo
TRNS
Transcat
2.50
Moderate Buy$114.0044.01% Upside
10x Genomics, Inc. stock logo
TXG
10x Genomics
2.38
Hold$15.8151.85% Upside

Current Analyst Ratings Breakdown

Latest TRNS, TXG, EYPT, and ALNT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/29/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
5/24/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/21/2025
Transcat, Inc. stock logo
TRNS
Transcat
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$106.00 ➝ $116.00
5/19/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$26.00 ➝ $18.00
5/16/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.00
5/15/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$14.00 ➝ $14.00
5/13/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.00
5/12/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$7.50 ➝ $6.50
5/12/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $15.00
5/10/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allient Inc. stock logo
ALNT
Allient
$516.06M1.11$4.93 per share6.86$15.52 per share2.18
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$56.04M11.09N/AN/A$5.66 per share1.60
Transcat, Inc. stock logo
TRNS
Transcat
$278.42M2.65$2.92 per share27.14$30.19 per share2.62
10x Genomics, Inc. stock logo
TXG
10x Genomics
$624.66M2.05N/AN/A$5.81 per share1.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allient Inc. stock logo
ALNT
Allient
$24.10M$0.5938.4418.49N/A2.64%10.80%4.75%8/6/2025 (Estimated)
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$70.79M-$2.41N/AN/AN/A-226.57%-43.01%-31.63%8/6/2025 (Estimated)
Transcat, Inc. stock logo
TRNS
Transcat
$13.65M$1.5642.7930.10N/A6.22%7.23%5.67%8/4/2025 (Estimated)
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$182.63M-$1.30N/AN/AN/A-29.90%-25.40%-19.69%8/6/2025 (Estimated)

Latest TRNS, TXG, EYPT, and ALNT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/19/2025Q4 2025
Transcat, Inc. stock logo
TRNS
Transcat
$0.66$0.64-$0.02$0.48$76.40 million$77.13 million
5/8/2025Q1 2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.45-$0.36+$0.09-$0.28$131.91 million$154.88 million
5/7/2025Q1 2025
Allient Inc. stock logo
ALNT
Allient
$0.33$0.46+$0.13$0.21$125.00 million$134.62 million
5/7/2025Q1 2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$0.65-$0.65N/A-$0.65$8.84 million$24.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allient Inc. stock logo
ALNT
Allient
$0.120.35%N/A20.34%N/A
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/AN/AN/AN/AN/A
Transcat, Inc. stock logo
TRNS
Transcat
N/AN/AN/AN/AN/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A

Latest TRNS, TXG, EYPT, and ALNT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/7/2025
Allient Inc. stock logo
ALNT
Allient
quarterly$0.030.4%5/22/20255/22/20256/5/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allient Inc. stock logo
ALNT
Allient
0.85
4.10
2.18
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/A
5.50
5.45
Transcat, Inc. stock logo
TRNS
Transcat
0.14
2.42
1.98
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/A
4.97
4.26

Institutional Ownership

CompanyInstitutional Ownership
Allient Inc. stock logo
ALNT
Allient
61.57%
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
99.41%
Transcat, Inc. stock logo
TRNS
Transcat
98.34%
10x Genomics, Inc. stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
Allient Inc. stock logo
ALNT
Allient
15.60%
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
4.46%
Transcat, Inc. stock logo
TRNS
Transcat
2.30%
10x Genomics, Inc. stock logo
TXG
10x Genomics
9.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allient Inc. stock logo
ALNT
Allient
1,95016.93 million14.22 millionOptionable
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
12068.81 million65.02 millionOptionable
Transcat, Inc. stock logo
TRNS
Transcat
9209.32 million9.10 millionOptionable
10x Genomics, Inc. stock logo
TXG
10x Genomics
1,240123.13 million108.91 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Allient stock logo

Allient NASDAQ:ALNT

$33.83 -0.45 (-1.31%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$33.85 +0.02 (+0.06%)
As of 06/13/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allient Inc., together with its subsidiaries, designs, manufactures, and sells precision and specialty controlled motion components and systems for various industries in the United States, Canada, South America, Europe, and Asia-Pacific. It offers brush and brushless DC motors, brushless servo and torque motors, coreless DC motors, integrated brushless motor-drives, gearmotors, gearing, modular digital servo drives, motion controllers, optical encoders, active and passive filters, input/output modules, industrial communications gateways, light-weighting technologies, and other controlled motion-related products, as well as nano precision positioning systems, servo control systems, and digital servo amplifiers and drives. The company sells its products to end customers and original equipment manufacturers in vehicle, medical, aerospace and defense, and industrial markets through direct sales force, authorized manufacturers' representatives, and distributors. The company was formerly known as Allied Motion Technologies Inc. and changed its name to Allient Inc. in August 2023. Allient Inc. was incorporated in 1962 and is headquartered in Amherst, New York.

EyePoint Pharmaceuticals stock logo

EyePoint Pharmaceuticals NASDAQ:EYPT

$9.03 +0.17 (+1.92%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$9.04 +0.01 (+0.06%)
As of 06/13/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Transcat stock logo

Transcat NASDAQ:TRNS

$79.16 +1.77 (+2.29%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$79.01 -0.15 (-0.19%)
As of 06/13/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Transcat, Inc. provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services. This segment also provides CalTrak, a proprietary document and asset management system that is used to manage the workflow of its calibration service centers and customers' assets; and Compliance, Control and Cost, an online customer portal that provides its customers with web-based asset management capability, as well as a safe and secure off-site archive of calibration and other service records. The Distribution segment sells and rents test, measurement, and control instruments for customers' test and measurement instrumentation needs, as well as value added services, such as calibration/certification of equipment purchase, equipment rental, used equipment for sale, and equipment kitting. This segment markets and sells its products through website, digital and print advertising, proactive outbound sales, and an inbound call center. The company provides services and products to highly regulated industries, principally life science, which includes companies in the pharmaceutical, biotechnology, medical device, and other FDA-regulated industries; and additional industries, including aerospace and defense industrial manufacturing, energy and utilities, and other industries that require accuracy in processes and confirmation of the capabilities of their equipment. Transcat, Inc. was incorporated in 1964 and is headquartered in Rochester, New York.

10x Genomics stock logo

10x Genomics NASDAQ:TXG

$10.41 -0.17 (-1.61%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$10.56 +0.15 (+1.39%)
As of 06/13/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.